Literature DB >> 10690826

Comparison of the efficacy of betaxolol-brinzolamide and timolol-dorzolamide as suppressors of aqueous humor flow in human subjects.

R F Brubaker1, C J Ingram, E O Schoff, C B Nau.   

Abstract

OBJECTIVE: To compare the efficacy of combinations of betaxolol-brinzolamide and timolol-dorzolamide as suppressors of aqueous humor flow and ocular hypotensive agents.
DESIGN: Placebo-controlled, masked comparison of the two drug combinations. PARTICIPANTS: Twenty-five normal human volunteers with the fellow eye serving as control. METHODS OR TESTING: Fluorophotometric measurement of aqueous humor flow and pneumatonometric measurement of intraocular pressure. MAIN OUTCOME MEASURES: Aqueous humor flow and intraocular pressure.
RESULTS: The betaxolol-brinzolamide combination lowered aqueous flow 39% to 44%, and the timololdorzolamide combination lowered aqueous flow 51%. The betaxolol-brinzolamide combination lowered intraocular pressure 14% to 19%, and the timolol-dorzolamide combination lowered it 18% to 24%.
CONCLUSIONS: Both drug combinations were effective; the timolol-dorzolamide combination appeared to be the more effective of the two after short-term exposure (24 hours).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10690826     DOI: 10.1016/s0161-6420(99)00044-5

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  8 in total

1.  EFFECT OF INTRAOCULAR PRESSURE-LOWERING MEDICATIONS ON NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATMENT OUTCOMES IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENT TRIALS.

Authors:  Ehsan Rahimy; Gui-Shuang Ying; Wei Pan; Jason Hsu
Journal:  Retina       Date:  2019-04       Impact factor: 4.256

2.  Prolongation of activity of single intravitreal bevacizumab by adjuvant topical aqueous depressant (Timolol-Dorzolamide).

Authors:  Suk Ho Byeon; Oh W Kwon; Ji Hun Song; Sung Eun Kim; Yong Sik Park
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-08-06       Impact factor: 3.117

3.  Effect of Adjuvant Topical Dorzolamide-Timolol vs Placebo in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.

Authors:  Jason Hsu; Samir N Patel; Jeremy D Wolfe; Chirag P Shah; Eric Chen; Thomas L Jenkins; Turner D Wibbelsman; Anthony Obeid; Mikel Mikhail; Sunir J Garg; Allen C Ho; Allen Chiang; Marc J Spirn; James F Vander
Journal:  JAMA Ophthalmol       Date:  2020-05-01       Impact factor: 7.389

4.  Efficacy and safety of combination therapy with latanoprost after a change in therapeutic regimen from timolol to brinzolamide in Japanese adult patients with primary open-angle glaucoma and ocular hypertension: open, non-randomized 12-week study.

Authors:  Shusaku Ishikawa; Yoshimi Nakamura; Yuko Nakamura; Hiroshi Sakai; Shoichi Sawaguchi; Kazuo Terashima; Makoto Kanno; Hidetoshi Yamashita
Journal:  Clin Ophthalmol       Date:  2008-12

5.  Efficacy of adjuvant topical timolol-dorzolamide with intravitreal bevacizumab injection in diabetic macular edema: A contralateral eye study.

Authors:  Ahmad Mirshahi; Ramin Tadayoni; Navid Mohsenzadeh; Talieh Saeidi Rezvani; Mojtaba Abrishami
Journal:  J Curr Ophthalmol       Date:  2019-02-10

6.  Combination of Intravitreal Bevacizumab and Topical Dorzolamide versus Intravitreal Bevacizumab Alone for Diabetic Macular Edema: A Randomized Contralateral Clinical Trial.

Authors:  Farhad Fazel; Hossein Nikpour; Mohsen Pourazizi
Journal:  Biomed Res Int       Date:  2020-01-16       Impact factor: 3.411

Review 7.  Topical Medication Therapy for Glaucoma and Ocular Hypertension.

Authors:  Tao Wang; Linlin Cao; Qikun Jiang; Tianhong Zhang
Journal:  Front Pharmacol       Date:  2021-12-01       Impact factor: 5.810

8.  24-hour intraocular pressure in glaucoma patients randomized to receive dorzolamide or brinzolamide in combination with latanoprost.

Authors:  Yoshimi Nakamura; Shusaku Ishikawa; Yuko Nakamura; Hiroshi Sakai; Ichiko Henzan; Shoichi Sawaguchi
Journal:  Clin Ophthalmol       Date:  2009-07-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.